Akouos, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −$86.8M | −$48.9M | −$23.9M |
| Net income | −$86.7M | −$48.6M | −$25.7M |
| Total assets | $278.8M | $333.4M | $45.2M |
| Total liabilities | $45.1M | $22.7M | $19.3M |
| Equity | $233.7M | $310.6M | −$32.8M |
| EPS (diluted) | $-2.52 | $-2.77 | — |
| Shares out. | 34.4M | 34.4M | 997,165 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- —
- Net margin
- —
- Return on equity
- −37.1%
- Return on assets
- −31.1%
- Return on capital (ROCE)
- −33.1%
- Liabilities / assets
- 16.2%
- Debt / equity
- 0.19×
- Book value / share
- $6.79
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- 6.54safe
- Accruals / assets
- −8.2%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2028-10Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
- Phase 1/2Recruitingreadout ~2029-08Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Walker Paul Edward10% owner | Nov 30, 2022 | U | 4.3M | — |
| Sonsini Peter W.10% owner | Nov 30, 2022 | U | 4.3M | — |
| Sandell Scott D10% owner | Nov 30, 2022 | U | 4.3M | — |
| Makhzoumi Mohamad10% owner | Nov 30, 2022 | U | 4.3M | — |
| Florence Anthony A. Jr.10% owner | Nov 30, 2022 | U | 4.3M | — |
| Chang Carmen10% owner | Nov 30, 2022 | U | 4.3M | — |
| Behbahani Ali10% owner | Nov 30, 2022 | U | 4.3M | — |
| Baskett Forest10% owner | Nov 30, 2022 | U | 4.3M | — |
| New Enterprise Associates 16, L.P.10% owner | Nov 30, 2022 | U | 4.3M | — |
| Wellman Jennifer AnneOfficer — CHIEF OPERATING OFFICER | Nov 30, 2022 | U | 12,338 | — |
| Tzianabos ArthurDirector | Nov 30, 2022 | U | 26,930 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventDec 1, 2022
- Results of operationsNov 14, 2022
- Entered a material agreement · Other material eventOct 18, 2022
- Results of operationsAug 15, 2022
- Director / officer changeJul 26, 2022
- Shareholder voteJun 27, 2022
- Results of operationsMay 12, 2022
- Results of operationsMar 29, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2023
- SC 13G/AFeb 10, 2023
- SC 13G/AJan 10, 2023
- SC 13G/AJan 10, 2023
- 15-12GDec 12, 2022
- EFFECTDec 5, 2022
- 4FORM 4 SUBMISSIONDec 2, 2022
- 4FORM 4 SUBMISSIONDec 2, 2022
- 4FORM 4 SUBMISSIONDec 2, 2022
- 4FORM 4 SUBMISSIONDec 2, 2022
- 4FORM 4 SUBMISSIONDec 2, 2022
- 4FORM 4 SUBMISSIONDec 2, 2022
- 4FORM 4 SUBMISSIONDec 2, 2022
- 4FORM 4 SUBMISSIONDec 2, 2022
- 4FORM 4 SUBMISSIONDec 2, 2022